Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
Clinical trial NCT05394337 · RECRUITING
Trial details
- NCT number
- NCT05394337
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-23
- Primary completion
- 2028-12-31
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.